Trial Profile
A 24-month Randomised Parallel Group Single-blinded Multi-centre Phase 1 Pilot Study of AADvac1 in Patients With Non Fluent Primary Progressive Aphasia
Status:
Active, no longer recruiting
Phase of Trial:
Phase I
Latest Information Update: 02 Nov 2021
Price :
$35
*
At a glance
- Drugs AADvac 1 (Primary) ; Aluminium hydroxide
- Indications Primary progressive aphasia
- Focus Adverse reactions; Pharmacodynamics
- Acronyms AIDA
- Sponsors Axon Neuroscience
- 13 Nov 2019 Planned End Date changed from 1 Jul 2020 to 1 Nov 2020.
- 13 Nov 2019 Planned primary completion date changed from 1 Jul 2020 to 1 Nov 2020.
- 13 Nov 2019 Status changed from recruiting to active, no longer recruiting.